Literature DB >> 12053705

Clinical research in the private office setting--ethical issues.

Alan R Fleischman1, Jason E Klein.   

Abstract

A new model for performing clinical investigations has emerged in the United States which utilizes networks of physicians practicing in private office settings. This arrangement has sparked much controversy because of the potential conflicts of interest inherent in the dual roles of physician as clinician and investigator as well as the significant direct financial gains reported by some physicians which might impact on the interests of research subjects. We describe some of the ethical concerns and propose some procedural guidelines to safeguard the interests of research subjects participating in clinical trials in private physician offices. These safeguards include: requiring education of all investigators in research ethics, limiting financial incentives, disclosure to subjects of potential conflicts and financial arrangements, creation of an independent resource available to subjects to discuss concerns and answer questions, and development of educational materials to inform all potential subjects about important issues related to clinical research.

Mesh:

Year:  2002        PMID: 12053705      PMCID: PMC2194467     

Source DB:  PubMed          Journal:  Trans Am Clin Climatol Assoc        ISSN: 0065-7778


  13 in total

1.  Uneasy alliance--clinical investigators and the pharmaceutical industry.

Authors:  T Bodenheimer
Journal:  N Engl J Med       Date:  2000-05-18       Impact factor: 91.245

2.  Evaluation of conflict of interest in economic analyses of new drugs used in oncology.

Authors:  M Friedberg; B Saffran; T J Stinson; W Nelson; C L Bennett
Journal:  JAMA       Date:  1999-10-20       Impact factor: 56.272

3.  Visceral viewpoints. Constraint and consent - on being a patient and a subject.

Authors:  H M Spiro
Journal:  N Engl J Med       Date:  1975-11-27       Impact factor: 91.245

4.  Why are drug development programs growing in size and cost? A view from industry.

Authors:  J F Niblack
Journal:  Food Drug Law J       Date:  1997       Impact factor: 0.619

5.  Source of funding and outcome of clinical trials.

Authors:  R A Davidson
Journal:  J Gen Intern Med       Date:  1986 May-Jun       Impact factor: 5.128

6.  Trust, The fragile foundation of contemporary biomedical research.

Authors:  N E Kass; J Sugarman; R Faden; M Schoch-Spana
Journal:  Hastings Cent Rep       Date:  1996 Sep-Oct       Impact factor: 2.683

7.  The quality of drug studies published in symposium proceedings.

Authors:  M K Cho; L A Bero
Journal:  Ann Intern Med       Date:  1996-03-01       Impact factor: 25.391

8.  Attitudes toward clinical trials among patients and the public.

Authors:  B R Cassileth; E J Lusk; D S Miller; S Hurwitz
Journal:  JAMA       Date:  1982-08-27       Impact factor: 56.272

9.  Ethics of clinical trials. Do they help the patient?

Authors:  R J Levine
Journal:  Cancer       Date:  1993-11-01       Impact factor: 6.860

10.  Participation in a clinical trial: the patients' point of view.

Authors:  M E Mattson; J D Curb; R McArdle
Journal:  Control Clin Trials       Date:  1985-06
View more
  2 in total

1.  Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminology.

Authors:  Mitchell S von Itzstein; Elda Railey; Mary L Smith; Carol B White; George W Sledge; John R Howell; Wendy Lawton; Donna M Marinucci; Nisha Unni; David E Gerber
Journal:  Cancer       Date:  2020-01-22       Impact factor: 6.860

2.  Community hospital oversight of clinical investigators' financial relationships.

Authors:  Mark A Hall; Kevin P Weinfurt; Janice S Lawlor; Joëlle Y Friedman; Kevin A Schulman; Jeremy Sugarman
Journal:  IRB       Date:  2009 Jan-Feb
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.